Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. More Details
Flawless balance sheet and undervalued.
Share Price & News
How has Dawnrays Pharmaceutical (Holdings)'s share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2348 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 2348's weekly volatility (6%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 2348 exceeded the Hong Kong Pharmaceuticals industry which returned 18.5% over the past year.
Return vs Market: 2348 exceeded the Hong Kong Market which returned 27.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Dawnrays Pharmaceutical (Holdings)'s share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall StHas Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
2 weeks ago | Simply Wall StTrade Alert: The Co-Founder & Executive Chairman Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348), Kei Ling Li, Has Just Spent CN¥425k Buying A Few More Shares
1 month ago | Simply Wall StWhat Percentage Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) Shares Do Insiders Own?
Is Dawnrays Pharmaceutical (Holdings) undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 2348 (HK$1.54) is trading below our estimate of fair value (HK$3.94)
Significantly Below Fair Value: 2348 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 2348 is good value based on its PE Ratio (7.4x) compared to the HK Pharmaceuticals industry average (12.3x).
PE vs Market: 2348 is good value based on its PE Ratio (7.4x) compared to the Hong Kong market (11.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2348's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2348 is good value based on its PB Ratio (0.9x) compared to the HK Pharmaceuticals industry average (1.3x).
How is Dawnrays Pharmaceutical (Holdings) forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Dawnrays Pharmaceutical (Holdings) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Dawnrays Pharmaceutical (Holdings) performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2348 has high quality earnings.
Growing Profit Margin: 2348's current net profit margins (26.2%) are lower than last year (26.9%).
Past Earnings Growth Analysis
Earnings Trend: 2348's earnings have declined by 2.3% per year over the past 5 years.
Accelerating Growth: 2348's earnings growth over the past year (5%) exceeds its 5-year average (-2.3% per year).
Earnings vs Industry: 2348 earnings growth over the past year (5%) exceeded the Pharmaceuticals industry 3.9%.
Return on Equity
High ROE: 2348's Return on Equity (12.1%) is considered low.
How is Dawnrays Pharmaceutical (Holdings)'s financial position?
Financial Position Analysis
Short Term Liabilities: 2348's short term assets (CN¥1.5B) exceed its short term liabilities (CN¥479.9M).
Long Term Liabilities: 2348's short term assets (CN¥1.5B) exceed its long term liabilities (CN¥240.2M).
Debt to Equity History and Analysis
Debt Level: 2348 is debt free.
Reducing Debt: 2348 has no debt compared to 5 years ago when its debt to equity ratio was 0.6%.
Debt Coverage: 2348 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 2348 has no debt, therefore coverage of interest payments is not a concern.
What is Dawnrays Pharmaceutical (Holdings) current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 2348's dividend (4.22%) is higher than the bottom 25% of dividend payers in the Hong Kong market (1.94%).
High Dividend: 2348's dividend (4.22%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.01%).
Stability and Growth of Payments
Stable Dividend: 2348's dividend payments have been volatile in the past 10 years.
Growing Dividend: 2348's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (31.5%), 2348's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Shaojun Chen (42 yo)
Mr. Shaojun Chen has been the Chief Executive Officer at Dawnrays Pharmaceutical Holdings Ltd. since April 18, 2016 and Executive Director since January 8, 2018. Mr. Chen has long specialized in sales prom...
CEO Compensation Analysis
Compensation vs Market: Shaojun's total compensation ($USD910.26K) is above average for companies of similar size in the Hong Kong market ($USD292.01K).
Compensation vs Earnings: Shaojun's compensation has been consistent with company performance over the past year.
Experienced Management: 2348's management team is seasoned and experienced (15.7 years average tenure).
Experienced Board: 2348's board of directors are considered experienced (8.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 2348 insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Dawnrays Pharmaceutical (Holdings) Limited's company bio, employee growth, exchange listings and data sources
- Name: Dawnrays Pharmaceutical (Holdings) Limited
- Ticker: 2348
- Exchange: SEHK
- Founded: 1995
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$2.289b
- Shares outstanding: 1.50b
- Website: https://www.dawnrays.com
Number of Employees
- Dawnrays Pharmaceutical (Holdings) Limited
- CNT Tower
- Units 3001-02
- Wan Chai
- Hong Kong
Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. The company operate...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/07 10:12|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.